Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim
Information source: Sanofi
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Crohn Disease
Intervention: Sargramostim (Leukine) (Drug); Placebo (Drug)
Phase: Phase 3
Status: Terminated
Sponsored by: Genzyme, a Sanofi Company Official(s) and/or principal investigator(s): Medical Monitor, Study Director, Affiliation: Genzyme, a Sanofi Company
Summary
The purpose of this study is to evaluate whether treatment with Leukine in patients with
Crohn's disease who have previously responded to Leukine can be helped again, once they have
relapsed.
Clinical Details
Official title: Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (LeukineŽ) in Patients With Active Crohn's Disease and Prior Treatment Response to Sargramostim
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Proportion of patients achieving clinical response or remission
Secondary outcome: Proportion of patients achieving clinical response or remission
Detailed description:
On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE:
This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer
HealthCare, Inc.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- You must be 18 years or older.
- You must have active Crohn's disease at the time of screening.
- You must be 18 years or older.
- You must have active Crohn's disease at the time of screening.
- You must be able to give yourself an injection of study drug or have another person
who can help you give the injection.
- You must not be pregnant and agree to use birth control if you are a sexually active
male or female of childbearing potential.
Exclusion Criteria:
- You may not be pregnant or breastfeeding.
- You may not have a colostomy or ileostomy.
- You may not be taking prohibited medications.
- You may not have had GI surgery or a bowel obstruction in the last 6 months.
- You may not have ever taken this drug or drugs of similar type in the past.
Locations and Contacts
San Francisco, California 94117, United States
Atlanta, Georgia 30342, United States
New Orleans, Louisiana 70118-5799, United States
Boston, Massachusetts 02114-2696, United States
Morristown, New Jersey 07962-1956, United States
Philadelphia, Pennsylvania 19104-4399, United States
Houston, Texas 77030, United States
Additional Information
Click here and search for drug information provided by the FDA Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product
Starting date: July 2004
Last updated: December 2, 2013
|